Aflac (NYSE:AFL) Posts Earnings Results

Aflac (NYSE:AFL) announced its earnings results on Wednesday. The financial services provider reported $2.16 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.46, Briefing.com reports. Aflac had a return on equity of 16.51% and a net margin of 22.02%. The business had revenue of $2.95 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter in the prior year, the firm earned $1.84 earnings per share. The business’s revenue was down 40.4% compared to the same quarter last year.

Aflac Stock Down 4.8 %

Shares of NYSE AFL opened at $104.79 on Friday. The stock has a market cap of $58.69 billion, a P/E ratio of 15.78, a PEG ratio of 2.24 and a beta of 0.95. The company has a current ratio of 0.10, a quick ratio of 0.10 and a debt-to-equity ratio of 0.29. Aflac has a 12-month low of $75.07 and a 12-month high of $115.50. The business’s fifty day simple moving average is $110.58 and its 200-day simple moving average is $97.51.

Aflac Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Wednesday, November 20th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.91%. The ex-dividend date of this dividend is Wednesday, November 20th. Aflac’s payout ratio is currently 30.12%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AFL. TD Cowen began coverage on Aflac in a research report on Wednesday, October 9th. They issued a “hold” rating and a $102.00 price target for the company. Truist Financial upped their price target on Aflac from $82.00 to $100.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Citigroup upped their price target on Aflac from $84.00 to $93.00 and gave the company a “neutral” rating in a research report on Tuesday, July 23rd. Evercore ISI increased their price objective on Aflac from $84.00 to $90.00 and gave the stock an “underperform” rating in a research report on Thursday, September 26th. Finally, UBS Group increased their price objective on Aflac from $84.00 to $109.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 14th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $97.53.

Insider Buying and Selling at Aflac

In other Aflac news, Director Thomas J. Kenny sold 2,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $98.94, for a total value of $197,880.00. Following the sale, the director now directly owns 18,158 shares in the company, valued at $1,796,552.52. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.90% of the stock is owned by insiders.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.